骨质疏松合成代谢治疗新时代?罗莫索单抗、特立帕肽与抗骨吸收治疗真实世界两中心比较研究
该回顾性队列研究基于澳大利亚两家三级医院电子病历,比较罗莫索单抗(n=53)、特立帕肽(n=54)和抗骨吸收治疗(n=60)对骨密度的影响。罗莫索单抗组腰椎骨密度增益显著高于特立帕肽(11.3% vs 5.0%,p<0.001)和抗骨吸收治疗(11.3% vs 6.6%,p<0.001)。初治患者腰椎增益更大,既往抗骨吸收治疗时长与腰椎骨密度增益呈负相关。
要点
- 罗莫索单抗真实世界显著提升腰椎、全髋和股骨颈骨密度,腕部骨密度下降。
- 初治患者腰椎骨密度增益(14.0%)高于既往抗骨吸收治疗者(10.7%)。
- 既往抗骨吸收治疗时间越长,罗莫索单抗腰椎骨密度反应越弱。
核心结论
- 罗莫索单抗在真实世界中有效改善骨密度,尤其腰椎增益显著大于特立帕肽或标准抗骨吸收治疗。
- 既往抗骨吸收治疗可能减弱罗莫索单抗的合成代谢效应,初治患者可能获益最大。
研究设计与样本
- 特立帕肽(n=54)和抗骨吸收治疗(n=60)比较队列数据来自既往电子病历数据集。
主要发现
- 罗莫索单抗治疗使腰椎、全髋和股骨颈骨密度增加,腕部骨密度下降(p<0.05)。
- 腰椎平均骨密度增益:罗莫索单抗11.3±8.2%,显著高于特立帕肽5.0±8.6%(p<0.001)和抗骨吸收治疗6.6±6.1%(p<0.001)。
- 初治患者腰椎增益14.0±6.6%、全髋增益5.0±1.7%,既往抗骨吸收治疗者腰椎增益10.7±8.5%(p=0.220)、全髋增益1.9±5.8%(p=0.009)。
- 既往抗骨吸收治疗时长与罗莫索单抗腰椎骨密度增益呈负相关(r=-0.305,p=0.026)。
- 线性回归显示更多椎体骨折、更长既往抗骨吸收使用和更高基线腰椎骨密度均减弱罗莫索单抗的腰椎骨密度反应;罗莫索单抗优于特立帕肽和抗骨吸收治疗,特立帕肽与标准抗骨吸收治疗无显著差异。
临床怎么用
- 对于骨质疏松患者,罗莫索单抗可优先考虑用于初治或既往抗骨吸收治疗时间较短者,以最大化腰椎骨密度增益。
- 既往长期抗骨吸收治疗患者使用罗莫索单抗时,需预期腰椎骨密度反应可能减弱。
局限性
- 回顾性研究设计,样本量较小(罗莫索单抗组53例),比较队列来自既往数据集,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Romosozumab demonstrates strong real-world effectiveness in improving bone density, with particularly pronounced gains at the lumbar spine. Treatment-naïve patients derive the greatest benefit. Lumbar spine improvements surpass those achieved with teriparatide or anti-resorptive therapies, and longer prior exposure to anti-resorptives is associated with attenuated responses to romosozumab. INTRODUCTION: Osteoporosis is a progressive disease that leads to considerable morbidity. The osteoanabolic agent romosozumab has shown efficacy in clinical trials, enhancing bone mineral density (BMD) and reducing fracture risk. However, real-world evidence, particularly in patients receiving long-term anti-resorptive therapy, remains limited. This study aimed to characterise real-world outcomes of romosozumab use in an Australian cohort, identifying predictors of optimal response following standard anti-resorptive treatment. METHODS: This retrospective cohort study identified 53 patients treated with romosozumab from the electronic medical record (eMR) at tertiary hospitals between 2021 and 23 who had completed 12 months of therapy and where baseline and follow-up DXA scans were available for analysis. Comparative data for teriparatide and anti-resorptive treatment cohorts were obtained from prior eMR datasets (n = 54 and n = 60, respectively). RESULTS: Romosozumab treatment led to BMD increases at the lumbar spine (LS), total hip (TH), and femoral neck (FN), with a decrease at the wrist (p < 0.05). Mean BMD gains at LS were significantly higher with romosozumab than with teriparatide (11.3 ± 8.2% vs. 5.0 ± 8.6%, p < 0.001) and anti-resorptive treatment (11.3 ± 8.2% vs. 6.6 ± 6.1%, p < 0.001). Treatment-naïve patients achieved more pronounced gains at LS (14.0 ± 6.6%); TH (5.0 ± 1.7%) compared to those with prior anti-resorptive therapy (LS 10.7 ± 8.5%, p = 0.220; TH 1.9 ± 5.8%, p = 0.009). Duration of previous anti-resorptive treatment was inversely correlated with LS BMD gains on romosozumab (r = - 0.305, p = 0.026). Linear regression showed that more vertebral fractures, longer prior anti-resorptive use, and higher baseline LS BMD each attenuated the LS BMD response to romosozumab, with romosozumab outperforming teriparatide and anti-resorptives, while teriparatide showed no significant difference from standard anti-resorptives. CONCLUSION: Romosozumab provides real-world efficacy in BMD improvement, particularly at the LS, with significantly greater gains than those seen with teriparatide or standard therapies. Prior anti-resorptive use may attenuate romosozumab's anabolic effects, suggesting that treatment-naïve patients may benefit most from this therapy.
引用
- Richardson-Thornton I, Brennan SC, Liu L, et al. A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis. Osteoporos Int. 2026. PMID: 41860715. doi:10.1007/s00198-025-07808-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。